Phagocytic Cell Marker Analysis for Personalized Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods rely on population-derived average values, which are inadequate for early and personalized diagnosis of diseases, as they fail to account for individual variations in marker expression.
Innovation Solution
The method involves using phagocytic cells with different DNA contents (>2n and =2n) to determine disease-specific markers, allowing for personalized diagnosis, prognosis, and treatment by comparing profiles of these markers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If population-derived average values are used for diagnosis, then diagnostic methods can be simplified and applied to general populations, but measurement precision and early diagnosis accuracy deteriorate due to failure to account for individual variations
Solution Approach 1:
The patent segments the phagocytic cell population into distinct subpopulations based on DNA content (2n versus >2n cells), allowing differential analysis of disease markers within each segment. This segmentation enables the detection of disease-specific marker profiles that are characteristic of particular cell states, thereby improving measurement precision while maintaining the feasibility of using readily available phagocytic cells from blood or tissue samples.
2Measurement precision
If phagocytic cells with different DNA contents are used to detect disease markers, then personalized and early diagnosis accuracy is improved, but device complexity and analytical complexity increase due to the need to compare multiple cell populations
Solution Approach 1:
The patent uses phagocytic cells as intermediary carriers that have internalized and concentrated disease-specific markers from target cells. By analyzing the marker profiles within these phagocytic cells rather than directly analyzing the disease target, the method simplifies the detection process while maintaining high specificity. The phagocytic cells serve as a convenient intermediary that can be readily accessed from blood or tissue samples.
Solution Approach 2:
The patent changes the analytical parameter from general population averages to specific DNA content-based cell subpopulation analysis. By stratifying phagocytic cells according to their DNA content (2n versus >2n), the method creates distinct analytical groups that can be compared to identify disease-specific marker profiles, thereby improving diagnostic precision without requiring overly complex technological infrastructure.
3Ease of operation
If population averages are used for diagnostic thresholds, then ease of operation is maintained, but reliability of diagnosis deteriorates due to inability to detect individual disease states accurately
Solution Approach 1:
The patent introduces dynamic analysis by comparing marker profiles across different phagocytic cell subpopulations (2n versus >2n cells) rather than using static population averages. This dynamic comparison allows the diagnosis to adapt to the specific cellular composition and marker expression patterns of the individual patient, thereby improving reliability while maintaining operational simplicity through the use of standard flow cytometry or similar analytical techniques.
Data Source
AI summary
This invention provides methods of using phagocytic cells in the diagnosis, prognosis, or monitoring of diseases or conditions. The invention also provides methods of using phagocytic cells to identify markers of diseases or conditions.